Premium
Helicases − feasible antimalarial drug target for Plasmodium falciparum
Author(s) -
Tuteja Renu
Publication year - 2007
Publication title -
the febs journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 204
eISSN - 1742-4658
pISSN - 1742-464X
DOI - 10.1111/j.1742-4658.2007.06000.x
Subject(s) - malaria , plasmodium falciparum , biology , plasmodium (life cycle) , dead box , helicase , drug resistance , drug , virology , parasite hosting , plasmodium vivax , nucleic acid , pharmacology , microbiology and biotechnology , immunology , genetics , rna , computer science , gene , world wide web
Of the four Plasmodium species that cause human malaria, Plasmodium falciparum is responsible for the most severe form of the disease and this parasite is developing resistance to the major antimalarial drugs. Therefore, in order to control malaria it is necessary to identify new drug targets. One feasible target might be helicases, which are important unwinding enzymes and required for almost all the nucleic acid metabolism in the malaria parasite.